Summary.-112 Tunisian patients with rapidly progressing breast cancer (RPBC) were entered into a clinical trial evaluating combination chemotherapy as a primary form of treatment before surgery or radiotherapy. Three cycles of cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) were administered at monthly intervals; patients were then randomized to surgery or radiotherapy to control the primary tumour, and 12 more cycles of CMF followed local/regional therapy. RPBC was sensitive to CMF; after only 3 cycles, 11%' of evaluable patients showed complete remission and 78% had at least 250/ diminution in tumour size. The disease-free interval (DFI) was substantially greater in this series than in a previously reported series treated by surgery and/or radiotherapy alone. No difference in DFI was found between patients randomized to receive surgery and those randomized to receive radiotherapy. Postmenopausal patients responded to CMF as well as premenopausal patients. Combination chemotherapy appears to play an important role in the control of RPBC, an aggressive malignancy often resembling inflammatory breast cancer.
interval (DFI) was substantially greater in this series than in a previously reported series treated by surgery and/or radiotherapy alone. No difference in DFI was found between patients randomized to receive surgery and those randomized to receive radiotherapy. Postmenopausal patients responded to CMF as well as premenopausal patients. Combination chemotherapy appears to play an important role in the control of RPBC, an aggressive malignancy often resembling inflammatory breast cancer.
OVER THE PAST 10 YEARS we have reported the high frequency of an acute form of breast cancer in Tunisia called rapidly progressing breast cancer (RPBC) or poussee evolutive (PEV). Characterized by rapid growth (PEV 1) and/or objective signs of inflammation (PEV 2 and PEV 3), this form has a brief disease-free interval (DFI) despite vigorous local/regional treatment. Metastases occur frequently and manifest the same aggressiveness as the primary tumour, which explains the poor prognosis, the 5-year survival being under 20% (Mourali et al., 1975 Tabbane et al., 1977) .
Analysis of the natural history suggested that RPBC is mainly a systemic disease at the outset, needing systemic treatment to control the disseminated microfoci, and that local/regional treatment applied to the primary tumour is inadequate for long-term control. Therefore, a new study was initiated using chemotherapy as the major primary treatment modality and, after considering the drugs currently used for breast cancer, a regimen of cyclophosphamide, methotrexate and 5-fluorouracil (CMF) was selected because of its overall effectiveness already reported in advanced breast cancer (Carter, 1980) After physical examination and X-rays of the breast, chest and pelvis, supplemented by other examinations if needed, the patients were staged according to T, N, M, and PEV criteria as previously described (Mourali et al., 1975 Tabbane et al., 1977) . The diagnosis of PEV 1, the mildest form of RPBC, is subjective, determined only by history of rapid tumour growth without inflammatory signs. In PEV 2, the inflammation is limited to less than half the breast, while in PEV 3 inflammation involves more than half the breast.
Once the primary classification was made, patients underwent a surgical biopsy. If the tumour was small, it was frequently removed completely. For larger tumours, a quartier d'orange, including skin, was obtained for histological study. The diagnosis was made by frozen section, and when cancer was confirmed, an additional study was systematically carried out to detect occult abdominal metastasis; premenopausal patients were studied at the time of oophorectomy and postmenopausal patients were examined by laparoscopy. All patients aged less than 65 with no evidence of metastasis received an explanation of the protocol of treatment, which included chemotherapy (CMF) and randomization to surgery or radiotherapy. Those accepting the protocol were entered into the study.
The treatment protocol consisted of 3 cycles of CMF, followed by local/regional treatment with surgery or radiotherapy, and then 15 more cycles of CMF. The patients were allocated at random to surgery and radiotherapy in all cases when local/regional conditions permitted; in one patient, radiotherapy was contraindicated because the tumour was extensively ulcerated.
Under the CMF regimen, patients received the following at each cycle: oral cyclophosphamide, 100 WBC and platelet counts were made before the first and eighth day of each cycle. The patients' toxicities were graded from 0 to 2 according to the results of these counts (Bonadonna et al., 1977) to determint the dose of CMF as follows:
Grade 0 myelosuppression: The calculated dose was given. (Table I ) revealed a high frequency of large tumours (51% were T3 and 12.5% were T4) and of considerable regional lymph-node involvement (42% were N2); all were MO.
Initial response of the primary tumour to chemotherapy
For the evaluation of the tumour response to the first 3 cycles of CMF, 21 patients could not be used because the entire primary tumour was removed at the diagnostic biopsy. An additional 2 patients were excluded because they did not return for a third measurement. One patient could not be evaluated because she had no measurable tumour; the diagnosis had been made on the basis of a positive biopsy of an axillary lymph node and a positive cytology from the ipsilateral bleeding nipple.
Of the 88 evaluable patients, 10 (11%) showed complete response, 45 patients (51 %) had regression > 50% (partial response), 14 (16%) had tumour regression of 25-50% (objective improvement), while the remaining 19 (22%) patients did not respond to treatment (Table II) .
The initial response to chemotherapy was assessed with respect to the patient's age, the initial pre-treatment tumour size, (Table II) . Pre-treatment tumour size was also a factor, large tumours demonstrating less decrease than small ones (Table III) . Menopausal status did not influence tumour response (Table II) .
Effect of combined treatment (CMF and local/regional treatment) on length of remission For the overall response to therapy, all 112 patients were included in the analysis while they complied with the chemotherapy protocol. Forty-seven patients completed all 18 cycles of chemotherapy without developing metastases, 22 developed metastases during the course of chemotherapy, 12 were still under treatment free of disease, and 31 were dropped from the study (30 decided to terminate treatment and one had to be removed from the trial because of intractable cystitis), though they were retained in the analysis until they left the study. The overall response to therapy (Fig. 1 but the effect appeared to be less prominent in the PEV 3 category (Table IV) . However, no significance levels can be attributed to these purely historical comparisons.
Of the 112 patients entered into the study, 90 (Fig. 3) . A severe PEV grade (Fig. 1) and a large tumour before chemotherapy (Fig. 4) Because of the poor results in the control of RPBC or PEV in our previous series with local/regional treatment associated with surgical oophorectomy in premenopausal women, we initiated this study combining chemotherapy with treatment of the primary lesion to determine whether RPBC is sensitive to chemotherapy and will respond to a combination of systemic and local/regional treatment.
To the best of our knowledge, however, there have been no reports of chemotherapy as a primary modality in the treatment of breast cancer, and particularly in RPBC, which includes many cases of inflammatory breast cancer detected in our Institute. Whilst other workers have initiated aggressive chemotherapy protocols for the treatment of inflammatory breast cancer, their results have not yet been published.
Before discussing our results, it is important to note the effect of such a protocol on our patient population. Compliance in a long chemotherapy protocol with randomization of treatment of the primary was difficult for our patients, particularly those from rural areas. Protocol violations were more common in those randomized to surgery than to radiation, for example. It is unlikely, however, that more sophisticated hospital techniques would have detected earlier metastases and affected our patient population, even though 3 patients showed detectable metastases before randomization. In addition to X-ray and bone scan, laparotomy or laparoscopy was used routinely in our series and we frequently detected occult metastases by these procedures, which are not routinely applied by European and American hospitals. The aggressiveness of RPBC has provided us with an excellent indicator of the effectiveness of systemic chemotherapy. We were not only interested in the initial decrease in the size of the primary tumour, but also in prolongation of survival. Of the parameters that appeared to be the best predictors of initial response to chemotherapy, most important were age, tumour size, and PEV stage (PEV with prominent inflammatory signs generally did poorly).
While we found no difference in remission length between PEVI and PEV2 patients receiving radiation for control of the primary tumour and those receiving surgery, PEV3 patients treated with radiotherapy did slightly better than those treated with surgery.
Previous workers have suggested that both forms of local control involve significant risks, particularly because of their possible depression of the immune system. Primary surgery had been contraindicated in the treatment of PEV at the Institute Gustave-Roussy (France) where the PEV classification orig-inated, because it was considered that surgery would have an immunosuppressive effect and RPBC was thought to be the result of initial patient immunosuppression (Lacour & Hourtoule, 1967) . We have shown in our previous studies, however, that RPBC is associated with normal or increased cellular immunity (CMI) to microbial anti-:372 gens, chemical sensitizing agents, and tumour-related antigens (Mourali et al., 1978; Levine et al., 1981) . Stjernsward et al. (1976) had earlier warned of the possible risks of radiation-induced immunosuppression in the treatment of breast cancer, but in longitudinal studies on our patients (unpublished), both delayed hypersensitivity and in vitro evidence of CMI have remained intact in patients receiving surgery or radiotherapy, and neither regimen appears to offer significant advantages over the other. Our future studies will combine both modalities of treatment according to the areas of clinical involvement.
Another finding of importance was the similar response to our protocol in both pre-and postmenopausal patients. This was significant not only because it emphasized the importance of chemotherapy in postmenopausal patients who did not have oophorectomy at the initial staging, but also because it showed that chemotherapy can be beneficial in postmenopausal patients. Bonnadonna et al. (1977) had previously abandoned the CMF regimen in postmenopausal patients because of the poor results in their initial series, but they suggested that the failures in this group might have been due to the relatively short duration (9 cycles) of chemotherapy. Our favourable response with 18 cycles confirms their hypothesis, and prolonged chemotherapy should be considered in other clinical trials in postmenopausal patients.
Although not enough patients have been followed for long enough for us to determine the effect on length of remission and, ultimately, on survival, the relationship between decrease in tumour size and the length of remission, as well as the high frequency of initial response to chemotherapy, suggests to us that chemotherapy will play an important role in many of our patients. As seen in Table III , there already appears to be a significant increase in the median remission length in our patients receiving combination therapy over our initial series.
We are fully aware of the pitfalls in using historical controls, and we cannot make firm conclusions as to the long-term results of our treatment until all patients in the current group have been followed for 5 years (a relatively short follow-up is reasonable in our patients because of the fulminating nature of the disease in the vast majority). Our early results are promising, however, and will form the basis of future trials using other chemotherapeutic agents, an evaluation of the sequencing of treatment regimens, and close scrutiny of the variables that determine the response of our patients to treatment. This latter parameter, which has shown us that patients with PEV3, large tumours and extensive lymph-node involvement are likely to relapse earlier, has already demonstrated the need for more aggressive therapy in these patients.
Furthermore, since we know that -75% of patients respond to chemotherapy, we are evaluating whether an initial debulking procedure such as that described for Burkitt's lymphoma (Magrath et al., 1974) will improve our results, particularly with the routine use of radiotherapy in the treatment of RPBC.
